Statin-induced apoptosis and skeletal myopathy.

Over 100 million prescriptions were filled for statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) in 2004. Statins were originally developed to lower plasma cholesterol in patients with hypercholesterolemia and are the most effective drugs on the market in doing so. Because of the discovered pleiotropic effects of statins, the use has expanded to the treatment of many other conditions, including ventricular arrythmias, idiopathic dilated cardiomyopathy, cancer, osteoporosis, and diabetes. The elderly population is growing. Therefore, it is estimated that the number of statin users will also increase. Fortunately, the use of statins is relatively safe with few side effects. Myopathy is the most common side effect with symptoms ranging from fatigue, weakness, and pain to symptoms associated with rhabdomyolysis which is a life-threatening condition. The development of statin-induced rhabdomyolysis is rare occurring in approximately 0.1% of patients; however, the occurrence of less severe symptoms is underreported and may be 1-5% or more. Physical exercise appears to increase the likelihood for the development of myopathy in patients taking statins. It is thought that as many as 25% of statin users who exercise may experience muscle fatigue, weakness, aches, and cramping due to statin therapy and potentially dismissed by the patient and physician. The mechanisms causing statin-induced myopathy have not been elucidated; however, research efforts suggest that apoptosis of myofibers may contribute. The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptosis will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.

[1]  G. Maurer,et al.  Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. , 2006, Biochemical pharmacology.

[2]  P. Thompson,et al.  An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.

[3]  P. Hauschka,et al.  HMG-CoA reductase inhibitors induce apoptosis in pericytes. , 2006, Microvascular research.

[4]  P. Auberger,et al.  RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation , 2006, Cell Death and Differentiation.

[5]  K. Yudoh,et al.  Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[6]  K. Criswell,et al.  Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  K. Matsuyama,et al.  Statin‐induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein , 2005, The Journal of pharmacy and pharmacology.

[8]  J. Sacher,et al.  Delineation of Myotoxicity Induced by 3-Hydroxy-3-methylglutaryl CoA Reductase Inhibitors in Human Skeletal Muscle Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  F. Dammacco,et al.  Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. , 2005, Carcinogenesis.

[10]  K. Mangione,et al.  Potential adverse effects of statins on muscle. , 2005, Physical therapy.

[11]  H. Yoshida,et al.  [Machinery of programmed cell death]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[12]  W. Erl.  Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? , 2005, Current drug targets. Cardiovascular & haematological disorders.

[13]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[14]  W. H. Schaefer,et al.  Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. , 2004, Toxicology and applied pharmacology.

[15]  M. Crow,et al.  Apoptosis Repressor with Caspase Recruitment Domain Protects against Cell Death by Interfering with Bax Activation* , 2004, Journal of Biological Chemistry.

[16]  G. Dreyfus,et al.  Statins: much more than just a lipid-lowering therapy. , 2004, Indian heart journal.

[17]  D. Bredesen,et al.  Coupling endoplasmic reticulum stress to the cell death program , 2004, Cell Death and Differentiation.

[18]  J. Rosenberg,et al.  Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  B. Pike,et al.  Increased expression and processing of caspase‐12 after traumatic brain injury in rats , 2003, Journal of neurochemistry.

[20]  C. Leeuwenburgh,et al.  Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. , 2004, Free radical biology & medicine.

[21]  A. MacKenzie,et al.  Life and death decisions: the role of the IAPs in modulating programmed cell death , 2004, Apoptosis.

[22]  Wen-Sen Lee,et al.  Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. , 2003, Endocrinology.

[23]  U. Laufs,et al.  Isoprenoid metabolism and the pleiotropic effects of statins , 2003, Current atherosclerosis reports.

[24]  D. Vaux,et al.  Mammalian mitochondrial IAP binding proteins. , 2003, Biochemical and biophysical research communications.

[25]  M. Shibata,et al.  Activation of caspase-12 by endoplasmic reticulum stress induced by transient middle cerebral artery occlusion in mice , 2003, Neuroscience.

[26]  D. Lavond.  Role of the Nuclei in Eyeblink Conditioning , 2002, Annals of the New York Academy of Sciences.

[27]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[28]  Xianwu Li,et al.  Inhibition of Protein Geranylgeranylation and RhoA/RhoA Kinase Pathway Induces Apoptosis in Human Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[29]  C. Leeuwenburgh,et al.  The Role of Apoptosis in the Normal Aging Brain, Skeletal Muscle, and Heart , 2002, Annals of the New York Academy of Sciences.

[30]  Á. Pascual,et al.  3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. , 2002, Atherosclerosis.

[31]  C. Leeuwenburgh,et al.  Apoptosis in skeletal muscle with aging. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[32]  C. Leeuwenburgh,et al.  Cytochrome c release from mitochondria in the aging heart: a possible mechanism for apoptosis with age. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[33]  R. Liddington,et al.  Dimer formation drives the activation of the cell death protease caspase 9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Leeuwenburgh,et al.  Apoptosis and aging: role of the mitochondria. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  G. Kroemer.  B709 Mitochondrial Control of Cell Death , 2001, TheScientificWorldJournal.

[36]  L. Ellerby,et al.  Coupling Endoplasmic Reticulum Stress to the Cell Death Program , 2001, The Journal of Biological Chemistry.

[37]  H. Nakayama,et al.  A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. , 2001, Molecular cell.

[38]  Guido Kroemer,et al.  Apoptosis‐inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis , 2000, FEBS letters.

[39]  D. Green.  Apoptotic Pathways Paper Wraps Stone Blunts Scissors , 2000, Cell.

[40]  Guido Kroemer,et al.  Mitochondrio‐nuclear translocation of AIF in apoptosis and necrosis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Crow,et al.  ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. , 1999, Circulation research.

[42]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[43]  M MacFarlane,et al.  Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[44]  H. Nakagawa,et al.  Involvement of tyrosine phosphorylation in HMG‐CoA reductase inhibitor‐induced cell death in L6 myoblasts , 1999, FEBS letters.

[45]  A. Ortiz,et al.  3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. , 1998, Circulation research.

[46]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[47]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[48]  F Gambale,et al.  Inhibition of Bax channel-forming activity by Bcl-2. , 1997, Science.

[49]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[50]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[51]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[52]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.